Key Highlights

  • Dexcom (NASDAQ:DXCM) fell about 6.5% on Wednesday, October 21, 2026, while the S&P 500 rose 0.58%, the Dow gained 0.69% and the Nasdaq Composite added 1.05%.
  • The trigger was Abbott Laboratories (NYSE:ABT), whose Diabetes Care sales rose 6.7% on a comparable basis to USD 2.19 billion, with continuous glucose monitor sales up 7.7%.
  • Abbott reaffirmed the midpoint of its 2026 EPS guidance, but press reports described its growth outlook, including diabetes, as trimmed, which investors applied to the whole monitor category.
  • Dexcom had not yet reported its own third-quarter results, so the move was a sector read-through from a competitor rather than a response to a change in its own guidance.

A Read-Through Sell-Off

Dexcom (NASDAQ:DXCM), which makes continuous glucose monitors, wearable sensors that track blood sugar every few minutes, fell about 6.5% on Wednesday, October 21, 2026. The decline came on a strong day for equities: the S&P 500 rose 0.58%, the Dow Jones Industrial Average gained 360 points, or 0.69%, to 52,856, and the Nasdaq Composite added 1.05%. The move followed results from Abbott Laboratories (NYSE:ABT), its main rival through the FreeStyle Libre sensor line, which reported the same day. Abbott reported Diabetes Care sales of USD 2.19 billion, up 6.7% on a comparable basis, and glucose monitor sales up 7.7%. Abbott tightened its 2026 EPS range to USD 5.50 to USD 5.55 and guided to comparable sales growth of about 6.0%.

Why Abbott's Numbers Move Dexcom

For Dexcom (NASDAQ:DXCM), Abbott's diabetes figures act as the first public read on category demand each quarter, because the two companies hold most of the glucose monitor market. Investors value the category on growth, as sensors are disposable and replaced every one to two weeks, which creates recurring revenue tied to the number of users. Monitor growth of 7.7% at Abbott raised the question of whether demand from people with type 2 diabetes, the larger and newer pool of users, is expanding as fast as valuations assume. A relative move of about 7 percentage points against the S&P 500, on simple arithmetic, shows how much of that assumption had been priced. Read-throughs can overshoot, since Abbott's figures blend pricing, geography and product mix that may differ for Dexcom.

Risks and What to Watch

The first risk for Dexcom (NASDAQ:DXCM) is that slower category growth proves real, which would pressure its valuation multiple even with steady execution. The second is pricing, as competition between the two main suppliers and coverage decisions by insurers and pharmacy benefit managers can lower revenue per user. The third is that the read-through itself proves wrong: if Dexcom reports faster growth than Abbott's monitor line, part of the move could reverse. Higher rates also weigh on growth valuations, with the federal funds range at 3.75% to 4.00%. Investors should watch Dexcom's own third-quarter report, the Fed decision on Wednesday, October 28, 2026 and the midterm elections on Tuesday, November 3, 2026.

Where Things Stand

The answer is that Dexcom (NASDAQ:DXCM) fell about 6.5% because investors read Abbott's 7.7% glucose monitor growth and its growth outlook as a signal for the whole category. Dexcom had not yet reported, so the move rests on inference from a competitor. Its own results will test that inference. The next catalysts are Dexcom's third-quarter report, the Fed decision on October 28 and the midterm elections on November 3. Read-throughs are not forecasts, and this is not investment advice.